Associate professor
+420 495 833 447
jan.korabecny@fnhk.cz
ORCID: 0000-0001-6977-7596
Jan obtained his doc. in 2021 at the Faculty of Pharmacy in Hradec Kralove, Charles University in Prague. Currently, he is deputy head at the Biomedical Research Center (BRC), University Hospital Hradec Kralove. He is responsible for development of novel drug candidates related to Alzheimer disease treatment, novel anticancer drugs and reactivators of nerve agent-inhibited acetylcholinesterase. Besides the scientific activity, Jan is devoted to supervising teaching either pre-gradual students and doctoral students and he is a part of team of synthetic laboratory.
| assoc. prof. | (2021) | Charles University in Prague, Faculty of Pharmacy Hradec Kralove |
| Ph.D. | (2012) | Charles University in Prague, Faculty of Pharmacy Hradec Kralove Doctoral thesis: „Synthesis of tetrahydroacridine based acetylcholinesterase inhibitors“ (supervisor: assoc.prof. RNDr. Veronika Opletalová, Ph.D.; supervisor consultant: prof. Ing Kamil Kuča, Ph.D.) |
| MSc. | (2008) |
Charles University in Prague, Faculty of Pharmacy Hradec Kralove |
Synthesis of tacrine-based cholinesterase inhibitors and other enzyme inhibitors participating in pathological processes in Alzheimer´s disease.
Development of novel anticancer drugs as radio- and chemo-sensitizing agents based on serine-threonine protein kinase inhibitors (ATM, ATR, DNA-PK and others)
Development of novel 5-HT3-D2 receptor modulators in schizophrenia treatment
Novel orphan drugs in narcolepsy
|
Since 2015 Since 2012 |
Workgroup on synthesis of novel drugs, Experimental neurobiology, National Institute of Mental Health, Klecany Postdoctoral fellow, Biomedical Research Centre (BRC), University Hospital Hradec Kralove |
| Since 2011 | Research fellow, Department of Toxicology, Faculty of Military Sciences, University of Defence |
| 4/2011–6/2011 |
Three months internship at Institute of Chemistry, Faculty of Science, Pavol Jozef Safarik University in Kosice (Slovakia); synthesis of new acetylcholinesterase inhibitors based on 7-methoxytacrine (supervisor Dr. Hamulakova) |
| 6/2013–7/2013 |
Two months internship at COBRA - Organic Chemistry, Biorganic Chemistry, University of Rouen (France), development of new acetylcholinesterase reactivators (supervisors Dr. Ludovic Jean, prof. P. Y. Renard) |
| 4/2014–5/2014 |
Two months internship at Korea Research Institute of Chemical Technology, Daejeon (South Korea), drug design and synthesis of novel acetylcholinesterase reactivators (supervisor Dr. Y.-S. Jung) |
| 4/2015–6/2015 |
two months internship at Faculty of Chemistry and Pharmacy, Insitute of Pharmacy and Food Chemistry, Julius-Maximilians-Universität (JMU) Würzburg (Germany), drug design and synthesis of novel anti-malaria agents (supervisor prof. Ulrike Holzgrabe) |
| 4/2016–5/2016 |
two months internship at Faculty of Pharmacy (Medical College), Jagiellonian University, Krakow (Poland), drug design and synthesis of novel anti-Alzheimer’s disease drugs (supervisor prof. Barbara Malawska) |
Czech chemical society – member
Society for Neuroscience – member
Czech Science Foundation - Medical physiology and neuroscience, diagnostics and therapies, translational research - evaluator
| Title: | From hit-to-lead candidate – development of novel agents to combat tuberculosis |
| Funding: | Grant Agency for Health Research of the Czech Republic |
| Schedule: | 2021–2024 |
| Role: | main investigator |
| Title: | Hybrid structures based on Amiridine as potential multitarget drugs for Alzheimer's disease |
| Funding: | Grant Agency Czech Republic, No. 20-29633J |
| Schedule: | 2020–2022 |
| Role: | main investigator |
| Title: | Specific serotonin-dopamin modulators and their potential in the model of induced psychosis |
| Funding: | Grant Agency Czech Republic, No. 19-11332S |
| Schedule: | 2019–2021 |
| Role: | main investigator |
| Title: | Novel therapeutic approaches in narcolepsy |
| Funding: | Grant Agency Czech Republic, No. 17-08596S |
| Schedule: | 2017–2019 |
| Role: |
main investigator |
| Title: | Development of squaric acid derivatives as potential drugs to confront neurodegeneration |
| Funding: | University Hospital in Hradec Kralove |
| Schedule: | 2018 |
| Role: | team member |
| Title: | Long-term development plan 1011 |
| Funding: | Ministry of Defence |
| Schedule: | 2012–2017 |
| Role: | team member |
| Since 2021 | Charles University in Prague, Faculty of Pharmacy Hradec Kralove |
| Since 2016 | Jagiellonian University in Krakow, Poland |
| Since 2015 |
Spanish National Research Council, Madrid, Spain |
| Since 2013 | University of Bologna, Italy |
| Since 2013 | Korean Research Insitute of Chemical Technology, Daejeon, South Korea |
| Since 2011 | University of P. J. Safarik, Science Faculty, Department of Organic Chemistry, Kosice, Slovakia |
|
2021–dosud 2020–dosud 2019–dosud 2018–dosud Since 2017 Since 2015 2011–2017 2013–2017
2010–2013 |
Mgr. Martin Kufa; doktorské studium; školitel specialista Lenka Nevosádová; magisterské studium, školitel specialista Ing. Vladimír Finger; doktorské studium; školitel specialista Ing. Barbora Svobodová; doktorské studium; školitel Ing. Jan Konečný; doctoral study; supervisor consultant Mgr. Lukáš Górecki; doctoral study; supervisor Mgr. Katarína Špilovská, Ph.D.; doctoral study; supervisor Mgr. Martin Andrš, Ph.D.; doctoral study; supervisor consultant Mgr. Eugenie Nepovimová, Ph.D.; doctoral study; supervisor Eugenie Nepovimová, pre-gradual student, supervisor consultant |
| 2011–2013 | Martin Andrš, pre-gradual student, supervisor consultant |
| 2011–2014 | Kateřina Babková, pre-gradual student, supervisor consultant |
| Pavla Čábelová, pre-gradual student, supervisor consultant | |
| 2012–2014 | Aleš Ondřejíček, pre-gradual student, supervisor consultant |
| Tadeáš Pešek, pre-gradual student, supervisor consultant | |
| Jan Král, pre-gradual student, supervisor consultant | |
| Jakub Jeřábek, pre-gradual student, supervisor consultant | |
| 2010 | Bc. Dominika Žofková, bachelor degree, supervisor |
| 2012 | Bc. Eva Neradová, bachelor degree, supervisor |
| 2008–2012 | Lecturing Pharmaceutical chemistry at the Department of Pharmaceutical chemistry and Drug Control, Faculty of Pharmacy in Hradec Kralove |
| 2011–today | Lecturing military toxicology at Faculty of Military Health Sciences |
| 2016 | Lecturing organic chemistry at the Department of Chemistry, Faculty of Sciences, University of Hradec Králové |
| 2008 | Award of Penta society for the best diploma thesis at the Department of inorganic and organic chemistry (titled Synthesis of differently substituted arylguaindines as potential drug candidates VI.) |
| 2010 | Honored by Czech Neuropsychopharmacological society for the best poster presentation (authors, title: Korabecny, J.; Holas, O.; Musilek, K.; Opletalova, V.; Pohanka, M.; Kuca, K. Newly prepared derivatives of 7-MEOTA. 52. Czech and Slovak psychopharmacological conference, Lazne Jesenik (Czech republic) 6.-10.1.2010, Supplementum 1, 2010, p. 45.) |
| 2013 |
Honored by Czech Neuropsychopharmacological society for the best poster presentation (authors, title: Hroudova, J.; Fisar Z., Raboch, J.; Korabecny, J.; Kuca, K. In vitro účinky inhibitorů acetlycholinestráz na aktzivitu monoaminooxidáz a NADH dehydrogenázy. 55. Czech and Slovak psychopharmacological conference, Lazne Jesenik (Czech republic) 4.-8.1.2013, Supplementum 1, 2013, p. 65.) |
| 2013 |
Best poster award (authors, title: Kuca, K.; Musilek, K.; Jun, D.; Zdarova-Karasova, J.; Kunes, M.; Soukup, O.; Korabecny, O.; Sepsova, V.; Hrabinova, M. Novel acetylcholinesterase reactivators – antidotes against nerve agents. International Conference on Pharmacology and Drug Development Singapore (Singapore) 9. – 11. 12. 2013.) |
| 2015 |
Best poster award (authors, title: Svobodova, L.; Nepovimova, E.; Korabecny, J.; Kucerova-Chlupacova, M.; Kuca, K. Tacrine-Benzothiazole Hybrids - Novel Multitarget Agents To Combat Alzheimer’s Disease. EPSA Annual Congress in Toulouse, Science day (Toulouse, France) 30.3.2015 |
| 2015 |
Best publication award for 2014 in neuroscience research awarded by Czech Alzheimer Society (Nepovimova, E.; Uliassi, E.; Korabecny, J.; Peña-Altamira, L.E.; Samez, S.; Pesaresi, A.; Garcia, G.E.; Bartolini, M.; Andrisano, V.; Bergamini, C.; Fato, R.; Lamba, D.; Roberti, M. Kuca, K.; Monti, B.; Bolognesi, M.L. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem. 2014, 57, 8576 8589. IF = 5.480.) |
| 2016 |
Faculty of Military Health Sciences Dean’s award for scientific contribution in 2015 |
(dated 5/2021)
Mezeiova, E.; Janockova, J.; Andrys, R.; Soukup, O.; Kobrlova, T.; Muckova, L.; Pejchal, J.; Simunkova, M.; Handl, J.; Micankova, P.; Capek, J.; Rousar, T.; Hrabinova, M.; Nepovimova, E.; Marco-Contelles, J.L.; Valko, M.; Korabecny, J. 2-Propargylamino-Naphthoquinone Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease. Eur. J. Med. Chem., 2021, 211, 113112. DOI: 10.1016/j.ejmech.2020.113112. IF2019 = 5,573. AIS2019 = 0,795.
Gorecki, L.; Hepnarova, V.; Zdarova Karasova, J.; Hrabinova, M.; Courageux, C.; Dias, J.; Kucera, T.; Kobrlova, T.; Muckova, L.; Prchal, L.; Malinak, D.; Jun, D.; Musilek, K.; Worek, F.; Nachon, F.; Soukup, O.; Korabecny, J. Development of versatile and potent monoquaternary reactivators of acetylcholinesterase. Arch. Toxicol., 2021, 95(3), 985-1001. DOI: 10.1007/s00204-021-02981-w. IF2019 = 5,059. AIS2019 = 1,120.
Kaniakova, M.; Korabecny, J.; Holubova, K.; Kleteckova, L.; Chvojkova, M.; Hakenova, K.; Prchal, L.; Novak, M.; Dolezal, R.; Hepnarova, V.; Svobodova, B.; Kucera, T.; Lichnerova, K.; Krausova, B.; Horak, M.; Vales, K.; Soukup, O. 7-phenoxytacrine is a dually acting drug with neuroprotective efficacy in vivo. Biochem. Pharmacol., 2021, 186, 114460. DOI: 10.1016/j.bcp.2021.114460. IF2019 = 4,960. AIS2019 = 1,093.
Jirkovska, A.; Karabanovich, G.; Kubes, J.; Skalicka, V.; Melnikova, V.; Korabecny, J.; Kucera, T.; Jirkovsky, E.; Novakova, L.; Bavlovic Piskackova, H.; Skoda, J.; Sterba, M.; Austin, C.; Simunek, T.; Roh, J. Structure-activity relationship study of dexrazoxane analogues reveals ICRF-193 as the most potent bisdioxopiperazine against anthracycline toxicity to cardiomyocytes due to its strong topoisomerase IIβ interactions. J. Med. Chem., 2021,. DOI: 10.1021/acs.jmedchem.0c02157. IF2019 = 6,205. AIS2019 = 1,565.
Pasieka, A.; Panek, D.; Jończyk, J.; Godyń, J.; Szałaj, N.; Latacz, G.; Tabor, J.; Mezeiova, E.; Chantegreil, F.; Dias, J.; Knez, D.; Lu, J.; Pi, R.; Korabecny, J.; Brazzolotto, X.; Gobec, S.; Höfner, G.; Wanner, K.; Więckowska, A.; Malawska, B. Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzymes butyrylcholinesterase and β-secretase, γ-aminobutyric acid transporters and neurotoxic protein aggregation. Eur. J. Med. Chem., 2021, 218, 113397. DOI: 10.1016/j.ejmech.2021.113397. IF2019 = 5,573. AIS2019 = 0,795.
Ismaili, L.; Monnin, J.; Etievant, A.; Arribas, R.; Viejo, L.; Refouvelet, B.; Soukup, O.; Janockova, J.; Hepnarova, V.; Korabecny, J.; Kucera, T.; Jun, D.; Andrys, R.; Musilek, K.; Baguet, A.; García-Frutos, E.; De Simone, A.; Andrisano, V.; Bartolini, M.; de los Rios, C.; Marco-Contelles, J.; Haffen, E. (±)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and antiaggregating properties for Alzheimer's Disease. ACS Chem. Neurosci., 2021, 12(8), 1328-1342. DOI: 10.1021/acschemneuro.0c00803. IF2019 = 4,486. AIS2019 = 1,156.
Gorecki, L.; Uliassi, E.; Bartolini, M.; Janockova, J.; Hrabinova, M.; Hepnarova, V.; Prchal, L.; Muckova, L.; Pejchal, J.; Zdarova Karasova, J.; Mezeiova, E.; Benkova, M.; Kobrlova, T.; Soukup, O.; Petralla, S.; Monti, B.; Korabecny, J.; Bolognesi, M.L. Phenothiazine-Tacrine Heterodimers: Pursuing Multi-Target Directed Approach in Alzheimer’s Disease. ACS Chem. Neurosci., 2021, just accepted. DOI: 10.1021/acschemneuro.1c00184. IF2019 = 4,486. AIS2019 = 1,156.
Gorecki, L.; Misiachna, A.; Damborsky, J.; Dolezal, R.; Korabecny, J.; Cejkova, L.; Hakenova, K.; Chvojkova, M.; Zdarova Karasova, J.; Prchal, L.; Novak, M.; Kolcheva, M.; Kortus, S.; Vales, K.; Horak, M.; Soukup, O. Structure-Activity Relationships of Dually-Acting Acetylcholinesterase Inhibitors Derived from Tacrine on N-Methyl-D-Aspartate Receptors. Eur. J. Med. Chem., 2021, 219, 113434. DOI: 10.1016/j.ejmech.2021.113434. IF2019 = 5,573. AIS2019 = 0,795.
Gorecki, L.; Andrs, M.; Korabecny, J. Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer. Cancers, 2021, 13(4), 795. DOI: 10.3390/cancers13040795. IF2019 = 6,126. AIS2019 = 1,436.
Soukup, O.; Benkova, M.; Dolezal, R.; Sleha, R.; Malinak, D.; Salajkova, S.; Markova, A.; Hympanova, M.; Prchal, L.; Ryskova, L.; Hobzova, L.; Sepčić, K.; Gunde-Cimerman; N.; Korabecny, J.; Jun, D.; Bostikova, V.; Bostik, P.; Marek, J. The wide-spectrum antimicrobial effect of novel N-alkyl monoquaternary ammonium salts and their mixtures; the QSAR study against bacteria. Eur. J. Med. Chem., 2020, 203, 112584. DOI: 10.1016/j.ejmech.2020.112584. IF2019 = 5,572. AIS2019 = 0,795.
Mezeiova, E.; Janockova, J.; Konecny, J.; Kobrlova, T.; Benkova, M.; Dolezal, R.; Prchal, L.; Karasova-Zdarova, J.; Soukup, O.; Korabecny, J. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia. Bioorg. Chem., 2020, 103, 104179. DOI: 10.1016/j.bioorg.2020.104179. IF2019 = 4,831. AIS2019 = 0,643.
Benek, O.; Korabecny, J.; Soukup, O. A Perspective on Multi-target Drugs for Alzheimer's Disease. Trends Pharmacol. Sciences, 2020, 41(7), 434-445. DOI: 10.1016/j.tips.2020.04.008. IF2019 = 13,503. AIS2019 = 3,946.
Mezeiova, E.; Soukup, O.; Korabecny, J. Huprines – an insight into synthesis and biological properties. Russ. Chem. Rev., 2020, 89(10), 999-1039. DOI: 10.1070/RCR4938. IF2019 = 4,750. AIS2019 = 0,777.
Juza, R.; Vlcek, P.; Mezeiova, E.; Musilek, K.; Soukup, O.; Korabecny, J. Recent Advances with 5-HT3 Modulators for Neuropsychiatric and Gastrointestinal Disorders. Med. Res. Rev. 2020, 40, 1593-1678. DOI: 10.1002/med.21666. IF2019 = 9,300. AIS2019 = 2,144.
Gorecki, L.; Andrs, M.; Rezacova, M.; Korabecny, J.Discovery of ATR Kinase Inhibitor Berzosertib (VX-970, M6620): Clinical Candidate for Cancer Therapy. Pharmacol. Therapeut., 2020, 210, 107518. DOI: 10.1016/j.pharmthera.2020.107518. IF2019 = 10,557. AIS2019 = 2,858.
Pospisilova, M.; Andrs, M.; Seifrtova, M.; Havelek, R.; Jun, D.; Tomsik, P.; Prchal, L.; Dolezal, R.; Tichy, A.; Kucera, T.; Korabecny, J.; Rezacova, M. Novel quinazolin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity. Bioorg. Chem., 2019, 82, 204-210. DOI: 10.1016/j.bioorg.2018.10.001. IF2019 = 4,831. AIS2019 = 0,643
Gorecki, L.; Junova, L.; Kucera, T.; Hepnarova, V.; Prchal, L.; Kobrlova, T.; Muckova, L.; Soukup, O.; Korabecny, J. Tacroximes - novel unique compounds for the recovery of organophosphorus-inhibited acetylcholinesterase. Fut. Med. Chem., 2019, 11(20), 2625-2634. DOI: 10.4155/fmc-2019-0027. IF2019 = 3,607. AIS2019 = 0,845.
Karabanovich, G.; Dusek, J.; Savkova, K.; Pavlis, O.; Pavkova, I.; Korabecny, J.; Kucera, T.; Kocova Vlckova, H.; Huszár, S; Konyarikova, Z.; Konecna, K.; Jandourek, O.; Stolarikova, J.; Kordulakova, J.; Vavrova, K.; Pavek, P.; Klimesova, V.; Hrabalek, A.; Mikusova, K.; Roh, J. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2'-Oxidase. J. Med. Chem., 2019, 62(17), 8115-8139. DOI: 10.1021/acs.jmedchem.9b00912. IF2019 = 6,205. AIS2019 = 1,570.
Korabecny, J.; Spilovska, K.; Mezeiova, E.; Benek, O.; Juza, R.; Kaping, D.; Soukup, O. A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease. Curr. Med. Chem., 2019, 26(30), 5625-5648. DOI: 10.2174/0929867325666180517094023. IF2019 = 4,184. AIS2019 = 0,745.
Gorecki, L.; Soukup, O.; Kucera, T.; Malinak, D.; Jun, D.; Kuca, K.; Musilek, K.; Korabecny, J. Oxime K203 – A drug candidate for the treatment of tabun intoxication. Arch. Toxicol., 2019, 93(3), 673-691. DOI: 10.1007/s00204-018-2377-7. IF2019 = 5,059. AIS2019 = 1,122.
Gorecki, L.; Andrys, R.; Schmidt, M.; Kucera, T.; Psotka, M.; Svobodova, B.; Hrabcova, V.; Hepnarova, V.; Bzonek, P.; Jun, D.; Kuca, K.; Korabecny, J.; Musilek, K. Cysteine-Targeted Insecticides against A. gambiae Acetylcholinesterase are neither Selective nor Reversible Inhibitors. ACS Med. Chem. Lett., 2020, 11(1), 65-71. DOI: 10.1021/acsmedchemlett.9b00477. IF2019 = 3,975. AIS2019 = 1,019.
Andrs, M.; Pospisilova, M.; Seifrtova, M.; Havelek, R.; Tichy, A.; Vejrychova, K.; Polednikova, M.; Forecki, L.; Jun, D.; Korabecny, J.; Rezacova, M. Purin-6-one and pyrrolo[2,3‐d]pyrimidin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity. Fut. Med. Chem., 2018, 10(17), 2029-2038. DOI: 10.4155/fmc-2018-0086. IF2018 = 3,617. AIS2018 = 0,909.
Kaniakova, M.; Kleteckova, L.; Lichnerova, K.; Holubova, K.; Skrenkova, K.; Korinek, M.; Krusek, J.; Smejkalova, T.; Korabecny, J.; Vales, K.; Soukup, O.; Horak, M. 7-Methoxyderivative of tacrine is a ‘foot-in-the-door’ open-channel blocker of GluN1/GluN2 and GluN1/GluN3 NMDA receptors with neuroprotective activity in vivo. Neuropharmacology, 2018, 140, 217-232. DOI: 10.1016/j.neuropharm.2018.08.010. IF2018 = 4,367. AIS2018 = 1,255.
Korabecny, J.; Nepovimova, E.; Cikankova, T.; Spilovska, K.; Vaskova, L.; Mezeiova, E.; Kuca, K.; Hroudova, J. Newly developed drugs for Alzheimer's disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission. Neuroscience, 2018, 370, 191-206. DOI: 10.1016/j.neuroscience.2017.06.034. IF2018 = 3,244. AIS2018 = 0,997.
Nepovimova, E.; Janockova, J.; Misik, J.; Kubik, S.; Stuchlik, A.; Vales, K.; Korabecny, J.; Mezeiova, E.; Dolezal, R.; Soukup, O.; Kobrlova, T.; Pham, N.L.; Nguyen, T.D.; Konecny, J.; Kuca, K. Orexin supplementation in narcolepsy treatment: a review. Med. Res. Rev., 2018, 39(3), 961-975. DOI: 10.1002/med.21550. IF2018 = 9,791. AIS2018 = 2,096.
Hrabcova, V.; Korabecny, J.; Manyova, B.; Matouskova, L.; Kucera, T.; Dolezal, R.; Musilek, K.; Gorecki, L.; Nepovimova, E.; Kuca, K.; Jun, D. Bis-isoquinolinium and bis-pyridinium acetylcholinesterase inhibitors: in vitro screening of probes for novel selective insecticides. RSC Advances, 2017, 7, 39279-39291. IF = 3.108.
Gorecki, L.; Korabecny, J.; Musilek, K.; Nepovimova, E.; Malinak, D.; Kucera, T.; Dolezal, R.; Jun, D.; Soukup, O.; Kuca, K. Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: a patent review (2006–2016). Exp. Opin. Ther. Pat., 2017, 27(9), 971-985. IF = 3.041.
Spilovska K.; Korabecny, J.; Sepsova, V.; Jun, D.; Hrabinova, M.; Jost, P.; Muckova, L.; Soukup, O.; Janockova, J.; Kucera, T.; Dolezal, R.; Mezeiova, E.; Kaping, D.; Kuca, K. A novel tacrine-scutellarin hybrids as multipotent anti-Alzheimer’s agents: design, synthesis and biological evaluation. Molecules 2017, 22(6), 1006. IF = 2.861.
Korabecny, J.; Nepovimova, E.; Cikankova, T.; Spilovska, K.; Vaskova, L.; Mezeiova, E.; Kuca, K.; Hroudova, J. Newly developed drugs for Alzheimer’s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission. Neuroscience 2017, just accepted. IF = 3.277
Babkova, K.; Korabecny, J.; Soukup, O.; Nepovimova, E.; Jun, D.; Kuca, K. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors. Fut. Med. Chem. 2017, 9(10), 1015-1038. IF = 3.556
Mezeiova, E.; Korabecny, J.; Sepsova, V.; Hrabinova, M.; Jost, P.; Muckova, L.; Kucera, T.; Dolezal, R.; Misik, J.; Spilovska, K.; Pham, N.L.; Pokrievkova, L.; Roh, J.; Jun, D.; Soukup, O.; Kaping, D.; Kuca, K. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy. Molecules, 2017, 22(8), 1265. IF = 2.861
